Long-Term Cognitive Function, Neuroimaging and Quality of Life in Primary CNS Lymphoma
Neurol 81:84-92, Doolittle, N.,et al, 2013
Primary CNS Posttransplant Lymphoproliferative Disease (PTLD): An International Report of 84 Cases in the Modern Era
Am J Transplant 13:1512-1522, Evens, A.M.,et al, 2013
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 69:1060-1062, Phan-Ba, R.,et al, 2011
Primary Central Nervous System Lymphoma
Arch Neurol 67:291-297, Gerstner,E.R. &Batchelor,T.T., 2010
Infectious and Non-Infectious Neurologic Complications in Heart Transplant Recipients
Medicine 89:166-175, Mu�oz,P., et al, 2010
Open Biopsy in Patients With Acute Progressive Neurologic Decline and Absence of Mass Lesion
Neurol 75:419-424, Schuette,A.J., et al, 2010
Treatment and Prognosis of Primary Central Nervous System Lymphoma
Up to Date Sept 2010, Hochberg,F.H.,et al, 2010
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009
Long-Term Outcome in PCNSL Patients Treated with High-Dose Methotrexate and Deferred Radiation
Neurol 70:401-402, Gerstner,E.R.,et al, 2008
Neurological Complications of Sickle Cell Disease
Eur Hematol Assoc 11:206-209, Kirkham,F.J., 2017
Neuroimaging Findings in Children and Young Adults with Neurotoxicity after CAR T-Cell Therapy for B-Cell Malignancies
Neurol 105:e214086, McGuire,J.L.,et al, 2025
Neurovascular Complications of Iatrogenic Fusarium solani Meningitis
NEJM 390:522-529, Strong, N.,et al, 2024
Confused About Confusion
NEJM 386:80-87, Spanjaart, A.M.,et al, 2022
Clinicopathologic Conference, Plasm-Cell Myeloma Post-Transplant Lymphoproliferative Disorder
NEJM 386:2508-2516, Case 20-2022, 2022
Encephalitis Induced by Immune Checkpoint Inhibitors
JAMA Neurol 78:864-873, Velasco, R.,et al, 2021
Chemotherapy-Associated Hyperammonemic Encephalopathy
Neurol 94:e874-e877, Briard, J.N.,et al, 2020
Clinicopathologic Conference, Human Herpesvirus 6-Related Meningoencephalitis
NEJM 378:659-669, Case 5-2018, 2018
A 77-year-old man presenting with episodic expressive aphasia
Neurol 90:e1822-e1826, Shanklin, A.,et al, 2018
Progressive Multifocal Leukoencephalopathy after Treatment with Nivolumab
Emerg Inf Dis 24:1594-1596, Martinot, M.,et al, 2018
CNS Posttransplant Lymphoproliferative Disorder
Neurol 89:e32-e37, Kesari, N.K.,et al, 2017
Sickle Cell Disease and Stroke
Stroke 45:e98-e100, Talahma, M.,et al, 2014
Sarcoidosis Occurring After Lymphoma: Report of 14 Patients and Review
Medicine 93:e121, London, J.et al, 2014
Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013
Plasmablastic Lymphoma after Standard-Dose Temozolomide for Newly Diagnosed Glioblastoma
Neurol 81:93-94, Clark, S.,et al, 2013
Spectrum of Neurologic Complications in Chronic Lymphocytic Leukemia
Clin Lymphoma Myeloma Leuk 12:164-179, Lopes da Silva, R., 2012
Sjogren Syndrome
emedicine.medscape.com,Oct, Miller,A.V., 2011
Evidence for Acute Neurotoxicity After Chemotherapy
Ann Neurol 68:806-815, Petzold,A.,et al, 2010
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
Polymyalgia Rheumatica
BMJ 336:765-769, Michet,C.J. &Matteson,E.L., 2008
Glatiramer Acetate--Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma
Arch Neurol 65:1378-1379, Madray,M.M.,et al, 2008
Risk Factors of Cerebral Vein and Sinus Thrombosis
Front Neurol Neurosci 23:23-54, de Freitas, G.R. & Bogousslavsky, J., 2008
Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After IschemicStroke, The OPTION Randomized Clinical Trial
JAMA doi:10.1001/JAMA.2026.0210, Ma,G.,et al, 2026
Patterns and Factors Associated with Cerebral Infarction on MRi in Tuberculous Meningitis: Secondary Anlysis of the ACT-TBM Trial
Stroke 57:856-864, Chandu,M.,et al, 2026
Alteplase for Posterior Circulation Ischemic Stropke at 4.5 to 24 Hours
NEJM 392:1288-1296, Yan,S.,et al, 2025
General AI May Revolutionize Neurology 0 Or It Might be Bad
JAMA Neurol doi 10.1001/JAMANEUROL.2025.0905, Westover,M.B. & Westover,A.M., 2025
Educational Strategies for Clinical Supervision of Artificial Intelligence Use
NEJM 393:786-797, Abdulnour,R-E. E.,et al, 2025
Endovascular Treatment in Acute Ischemic Stroke Due to Occlusion of Medium or Distal Vessels
Neurol 105:e214015, Palaiodimou,L.,et al, 2025
AI in Neurology: Everything, Everywhere, all at One PRT 2:Speech, Sentience, Scruples, and Service
Ann Neurol 98:431-447, Rizzo, M., 2025
General AI May Revolutionize Neurology-Or It Might Be Bad
JAMA Neurol 82:977-978, Westover,M.B., & Westover A.M., 2025
Endovascular Thrombectomy Versus Best Medical Therapy for Large Vessel Occlusion Stroke Beyond 24 Hours: A Systematic Review and Meta-Analysis
Stroke 56:3127-3137, Rodriguez-Caliemnes,A.,et al, 2025
Effectiveness of Endovascular Treatment for Acute Mild Basilar Artery Occlusion Stroke:A Multicenter Real-World Study
Stroke 56:3187-3198, Xiao,Y.,et al, 2025
Acromegaly
NEJM 393:1926-1939, Giustina,A. & Colao,A.,, 2025
Transcarotid Arter Revascularization Expanding Our Arsenal for the Management of Symptomatic Carotid Artery Stenosis
Stroke 55:931-933, Palaiodimou,L, 2024
Posttransplant Anti-GABAA Receptor Antibody-Associated Autoimmune Encephalitis
Neurol 102:e209245, Togni,C.L.,et al, 2024
Trial of Thrombectomy for Stroke with a Large Infarct of Unrestricted Size
NEJM 390:1677-1689, Costalat,V.,et al, 2024
Tenecteplase Versus Standard of Care for Minor Ischaemic Stroke with Proven Occlusion (TEMPO-2): A Randomised, Open Label, Phase 3 Superiority Trial
Lancet 403:2597-2605, Coutts,S.B.,et al, 2024
How Patients Are Using AI
BMJ 387:q2393, Stokel-Walker,C., 2024
Benefits, Limits, and Risks of GPT-4 as an AI Chatbot for Medicine
NEJM 388:1233-1239, Lee,P., et al, 2023
Iatrogenic Cerebral Amyloid Angiopaty Post Neurosurgery:Frequency, Clinical Profile, Radiological Features, and Outcome
Stroke 54:1214-1223, 1224, Kaushik,K.,et al, 2023